Business Context and Reporting Period
This Form 8-K was filed by Catalyst Biosciences, Inc. on May 26, 2016, reporting events occurring on May 20, 2016. The filing discloses the entry into a Material Definitive Agreement with CMC ICOS Biologics, Inc. (CMC) to support the development of the Company's next-generation FVIIa variant, CB 813d.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The only financial figure disclosed relates to the new agreement:
- Agreement Commitment: $3.8 million in total payments to CMC under the initial statement of work, contingent on the completion of applicable work stages.
Material Changes
The primary material change is the execution of a Development and Manufacturing Agreement. Key terms include:
- Scope: CMC will conduct manufacturing development and manufacture CB 813d for clinical trials on a fee-for-services basis.
- Intellectual Property: Catalyst Biosciences will own all IP developed related to CB 813d and receives a royalty-free, perpetual license to use CMC's IP necessary for commercial manufacturing.
- Term: Initial term of ten years or until all outstanding work stages are completed.
- Termination: Either party may terminate for material uncured breach or bankruptcy. Catalyst may terminate for any reason with prior notice. Termination is also permitted if manufacturing development cannot be completed for technical or scientific reasons.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance or management commentary on future performance. Risks and contingencies associated with the agreement include:
- Payment Obligations: If clinical manufacturing batches are cancelled or rescheduled, the Company remains obligated to pay a portion of manufacturing fees, less mitigated fees.
- Technical Risk: The agreement allows for termination if manufacturing development activities cannot be completed for technical or scientific reasons.
Investor Verification Checklist
- Verify the specific milestones and payment schedule within the $3.8 million commitment to CMC.
- Confirm the status of the CB 813d clinical trial program and the timeline for manufacturing development.
- Review the press release issued on May 24, 2016 (Exhibit 99.1) for additional context on the strategic partnership.
- Assess the impact of the $3.8 million commitment on the Company's current cash runway and liquidity position.